ArticleAmerican heart journal plus : cardiology research and practice2026
Multiethnic community cardio-metabolic risk factor screening in Northeast Florida: The VIDASANA Project.
Article in American heart journal plus : cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiometabolic risk disproportionately affects racially and ethnically diverse United States populations. Few community-based studies have examined the intersection of metabolic syndrome (MS), functional capacity, and cardiovascular disease (CVD) risk across multiple groups within a single region. Objective: To evaluate MS prevalence, functional capacity, and 10-year CVD risk in adults from diverse communities in Northeast Florida. Methods: A total of 345 adults were screened between 2017 and 2019 in a community-based, cross-sectional study. MS was defined by Adult Treatment Panel III criteria (≥3 of 5 thresholds). Functional capacity and 10-year CVD risk were assessed using Duke Activity Status Index (DASI), and Framingham Risk Score (FRS). Group differences were evaluated using appropriate univariate tests, and multivariable logistic regression identified independent predictors of MS ( Results: MS prevalence was highest among Hispanic (H) subjects (47%), followed by non-Hispanic Black (NHB, 35%) and Southeast Asian participants (SEA, 33%). Adjusted odds of MS were higher in H (OR 7.3, 95% CI 1.8-28.6) and SEA participants (OR 5.2, 95% CI 1.2-22.2) compared to non-Hispanic White (NHW) subjects. DASI scores were significantly lower in women and minority (H and SEA) populations. MS further reduced functional capacity in H ( Conclusions: This study identified marked disparities in MS prevalence, functional capacity, and cardiovascular risk across racial and ethnic groups with greater burden among minoritized populations across all domains. Findings support the need for more inclusive, culturally informed prevention strategies for diverse populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.